| 抗CD38单克隆抗体治疗多发性骨髓瘤研究进展 |
| |
| 引用本文： | 高 欣,杨融辉,廖爱军.抗CD38单克隆抗体治疗多发性骨髓瘤研究进展[J].现代肿瘤医学,2019,0(9):1617-1620. |
| |
| 作者姓名： | 高 欣 杨融辉 廖爱军 |
| |
| 作者单位： | 中国医科大学附属盛京医院第二血液内科，辽宁 沈阳 110022 |
| |
| 基金项目： | 沈阳市科技计划产业发展应用基础研究项目（编号:17-231-1-58） |
| |
| 摘 要： | 多发性骨髓瘤（multiple myeloma，MM）是一种血液系统恶性肿瘤，以骨髓内浆细胞克隆性增殖为特征，发病率占血液肿瘤的第二位。目前，MM的治疗取得了很大进展，患者的预后得到明显改善，但MM仍然是一种不可治愈的疾病。抗CD38单克隆抗体作为新的治疗药物被研究的越来越多，可以通过多种途径诱导MM细胞死亡。本文对抗CD38单克隆抗体在MM治疗中的临床应用作一综述。
|
| 关 键 词： | 多发性骨髓瘤 CD38 Daratumumab SAR650984 MOR202 |
Advances in anti-CD38 monoclonal antibody in the treatment of multiple myeloma |
| |
| Gao Xin,Yang Ronghui,Liao Aijun.Advances in anti-CD38 monoclonal antibody in the treatment of multiple myeloma[J].Journal of Modern Oncology,2019,0(9):1617-1620. |
| |
| Authors: | Gao Xin Yang Ronghui Liao Aijun |
| |
| Affiliation: | Department of Second Hematology，Shengjing Hospital of China Medical University，Liaoning Shenyang 110022，China. |
| |
| Abstract: | Multiple myeloma(MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow，accounting for the second highest incidence of hematological neoplasms.At present，great progress has been made in the treatment of MM，and the prognosis of patients has been significantly improved，but MM is still an incurable disease.Anti-CD38 monoclonal antibodies are being studied as new therapeutic agents and can induce MM cell death through multiple pathways.This article reviews the clinical application of anti-CD38 monoclonal antibody in MM treatment. |
| |
| Keywords: | multiple myeloma CD38 Daratumumab SAR650984 MOR202 |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
